Retatrutide, developed by Soma Pharmaceuticals , is gaining increasing attention as a innovative method for metabolic control . This innovative drug integrates the activity of a GLP-1 receptor stimulant and a GIP receptor agonist , intended to not only promote metabolic improvements but also address underlying metabolic factors. Preliminary human t